Actively Recruiting
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Led by Shandong Cancer Hospital and Institute · Updated on 2026-05-01
25
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer.
CONDITIONS
Official Title
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- ECOG performance status 0-1
- Confirmed unresectable locally advanced pancreatic cancer by pathology
- No prior systemic anti-tumor therapy for pancreatic cancer
- Primary pancreatic cancer or at least one measurable tumor lesion by RECIST 1.1
- Expected life expectancy greater than 3 months
- Blood counts: Absolute neutrophil count ≥ 1.0 x 10^9 cells/L, platelets ≥ 75 x 10^9 cells/L, hemoglobin ≥ 9.0 g/dl
- Liver and kidney function within defined limits: AST < 2.5 x ULN, ALT < 2.5 x ULN, creatinine ≤ 1.5 x ULN, total bilirubin ≤ 1.5 x ULN
You will not qualify if you...
- Diagnosis of other cancers within 3 years before enrollment
- Participation in other interventional clinical trials or use of investigational drugs/devices within 4 weeks
- Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, or drugs affecting T-cell receptors
- Use of systemic Chinese patent medicines with anti-tumor effects or immunomodulatory drugs within 2 weeks
- Abnormal blood routine, liver, kidney, or coagulation tests
- Significant dysfunction of major organs within 14 days before enrollment
- Pregnancy
- Inability or unwillingness to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Radiation Oncology, Shandong Cancer Hospital and Institute
Jinan, Shandong, China, 0531
Actively Recruiting
Research Team
J
Jinbo Yue, dorctor
CONTACT
L
Lei Xu, dorctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here